Abstract
Background Endometrial cancer is the most common gynaecological cancer in high-income countries. Elevated body mass index (BMI) is an established modifiable risk factor for this condition and is estimated to confer a larger effect on endometrial cancer risk than any other cancer site. However, the molecular mechanisms underpinning this association remain unclear. We used Mendelian randomization (MR) to evaluate the causal role of 14 molecular risk factors (hormonal, metabolic, and inflammatory markers) in endometrial cancer risk. We then evaluated and quantified the potential mediating role of these molecular traits in the relationship between BMI and endometrial cancer.
Methods and Findings Genetic instruments to proxy 14 molecular risk factors and BMI were constructed by identifying single-nucleotide polymorphisms (SNPs) reliably associated (P < 5.0 x 10-8) with each respective risk factor in previous genome-wide association studies (GWAS). Summary statistics for the association of these SNPs with overall and subtype-specific endometrial cancer risk (12,906 cases and 108,979 controls) were obtained from a GWAS meta-analysis of the Endometrial Cancer Association Consortium (ECAC), Epidemiology of Endometrial Cancer Consortium (E2C2), and UK Biobank. SNPs were combined into multi-allelic models and odds ratios (ORs) and 95% confidence intervals (95% CIs) were generated using inverse-variance weighted random-effects models. The mediating roles of the molecular risk factors in the relationship between BMI and endometrial cancer were then estimated using multivariable MR. In MR analyses, there was strong evidence that BMI (OR per SD increase: 1.88, 95% CI: 1.69 to 2.09, P = 3.87 x 10-31), total testosterone (OR per inverse normal transformed nmol/L increase: 1.64, 95% CI: 1.43 to 1.88, P = 1.71 x 10-12), bioavailable testosterone (OR per inverse normal transformed nmol/L increase: 1.46, 95% CI: 1.29 to 1.65, P = 3.48 x 10-9), fasting insulin (OR per natural log transformed pmol/L increase: 3.93, 95% CI: 2.29 to 6.74, P = 7.18 x 10-7) and sex hormone-binding globulin (SHBG, OR per inverse normal transformed nmol/L increase: 0.71, 95% CI: 0.59 to 0.85, P = 2.07 x 10-4) had a causal effect on endometrial cancer risk. Additionally, there was suggestive evidence that total serum cholesterol (OR per mg/dL increase: 0.90, 95% CI: 0.81 to 1.00, P = 4.01 x 10-2) had an effect on endometrial cancer risk. In mediation analysis using multivariable MR, we found evidence for a mediating role of fasting insulin (19% total effect mediated, 95% CI: 5 to 34%, P = 9.17 x 10-3), bioavailable testosterone (15% mediated, 95% CI: 10 to 20%, P = 1.43 x 10-8), and SHBG (7% mediated, 95% CI: 1 to 12%, P = 1.81 x 10-2) in the relationship between BMI and endometrial cancer risk. The primary limitations of this analysis include the assumption of linear relationships across univariable and multivariable analyses and the restriction of analyses to individuals of European ancestry.
Conclusions Our comprehensive Mendelian randomization analysis provides insight into potential causal mechanisms linking BMI with endometrial cancer risk and suggests pharmacological targeting of insulinemic and hormonal traits as a potential strategy for the prevention of endometrial cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EH is supported by a Cancer Research UK Population Research Committee Studentship (C18281/A30905). EH, VT, GDS, RMM, KR and JY are supported by Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). EH, ES, VT, GDS, RMM, and JY are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4) and the University of Bristol. JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). RMM is also supported by the NIHR Bristol Biomedical Research Centre which is funded by the NIHR and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. TMF is funded by the MRC (MR/T002239/1). TAO M is funded by a National Health and Medical Research Council Investigator Fellowship (APP1173170). Disclaimers: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care; where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from: the GWAS catalogue (https://www.ebi.ac.uk/gwas/downloads/summary-statistics)(Adult BMI {Yengo et al}; LDL-C, HDL-C, triglycerides, total serum cholesterol {Willer et al}; leptin {Folkersen et al}, endometrial cancer {O'Mara et al)) and the IEU Open GWAS catalogue (https://gwas.mrcieu.ac.uk/)(Glucose {Neale et al}). Data on fasting insulin (Lagou et al) were obtained from the MAGIC consortium (https://magicinvestigators.org/downloads/). Data on IGF-1 (Sinnott-Armstrong et al) are available here: https://doi.org/10.35092/yhjc.12355382. Data on IL-6 were obtained from results presented in Georgakis et al. Circulation: Genomic and Precision Medicine. 2020;13:e002872 (https://www.ahajournals.org/doi/10.1161/CIRCGEN.119.002872). Data on adiponectin were obtained from Dastani et al. PLoS Genet 8(3): e1002607. (https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1002607). Data on CRP were obtained from Ligthart et al. Am J Hum Genet. 2018 Nov 1;103(5):691-706 (https://www.cell.com/ajhg/fulltext/S0002-9297(18)30320-3). Data on testosterone (bioavailable and total) and SHBG were obtained by contacting Kate Ruth (k.s.ruth at exeter.ac.uk).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study involves only openly available human data, which can be obtained from: the GWAS catalogue (Adult BMI {Yengo et al}; LDL-C, HDL-C, triglycerides, total serum cholesterol {Willer et al}; leptin {Folkersen et al}, endometrial cancer {O'Mara et al)) and the IEU Open GWAS catalogue (Glucose {Neale et al}). Data on fasting insulin (Lagou et al) were obtained from the MAGIC consortium (https://magicinvestigators.org/downloads/). Data on IGF-1 (Sinnott-Armstrong et al) are available here: https://doi.org/10.35092/yhjc.12355382. Data on IL-6 were obtained from results presented in Georgakis et al. Circulation: Genomic and Precision Medicine. 2020;13:e002872 (https://www.ahajournals.org/doi/10.1161/CIRCGEN.119.002872). Data on adiponectin were obtained from Dastani et al. PLoS Genet 8(3): e1002607. (https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1002607). Data on CRP were obtained from Ligthart et al. Am J Hum Genet. 2018 Nov 1;103(5):691-706 (https://www.cell.com/ajhg/fulltext/S0002-9297(18)30320-3). Data on testosterone (bioavailable and total) and SHBG were obtained by contacting Kate Ruth (k.s.ruth at exeter.ac.uk).